Summary of JD Health International (6618.HK) Conference Call Company Overview - **Company**: JD Health International (6618.HK) - **Industry**: Healthcare Technology Key Financial Highlights - **2H25 Revenue**: Rmb38.2 billion, up 28% year-over-year (yoy), exceeding expectations by 5% compared to Goldman Sachs estimates and Visible Alpha Consensus Data [1] - **Non-IFRS Net Profit**: Rmb3 billion, a 38% yoy increase, beating estimates by 16% and 5% [1] - **Adjusted Net Profit Margin**: 7.8%, the highest margin for 2H in the company's history, with gross margin improving to 24.4%, up 0.8 percentage points from estimates [1] - **4Q25 Projections**: Revenue growth expected at 27% yoy and adjusted net profit growth at 30% yoy [1] Growth Drivers and Outlook - **Management Confidence**: Sustained growth momentum with FY26 revenue guidance of high-teens to 20% yoy, driven by strong drug and nutrition product sales, as well as advertising growth [2] - **Drug Sales Growth**: Expected to grow approximately 25% yoy in FY26, supported by original drugs and strong user mindshare [2] - **Nutrition Products**: Targeting around 15% yoy growth in FY26, benefiting from resource allocation and successful collaborations [2] - **Medical Devices**: Anticipated growth of about 10% yoy for FY26, reflecting steady industry growth [2] Margin and Profitability Insights - **Adjusted Operating Profit Margin**: Expected to remain at least flat yoy in FY26, benefiting from improved gross margins and advertising revenue growth [2] - **Investment in Technology**: Continuous improvement in gross margins is anticipated despite rising expenses due to investments in on-demand delivery and AI initiatives [2] Investment Rating and Price Target - **Rating**: Buy - **12-Month Target Price**: HK$75 per share, implying a 57.9% upside from the current price of HK$47.50 [3][9] Risks and Challenges - **Sales Growth Risks**: Potential for slower-than-expected sales growth in 2026, particularly in drug and non-drug categories [3][6] - **Margin Dynamics**: Concerns regarding margin dynamics due to ongoing investments in technology and competition from online pharmacies and e-commerce peers [6] Additional Financial Metrics - **Market Capitalization**: HK$151.5 billion / $19.4 billion [9] - **Revenue Forecasts**: Projected revenues for FY26 are Rmb83.1 billion, with EBITDA expected to reach Rmb4.1 billion [9] - **P/E Ratio**: Expected to be 19.1x in FY26 [9] Conclusion - JD Health International demonstrates strong financial performance with significant revenue and profit growth, driven by robust sales in drug and nutrition categories. The company maintains a positive outlook for FY26, although it faces potential risks related to sales growth and competitive pressures. The investment rating remains bullish with a substantial upside potential.